Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA grew its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 215.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,314 shares of the company’s stock after buying an additional 20,035 shares during the period. Massachusetts Financial Services Co. MA owned 0.05% of Twist Bioscience worth $1,324,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of TWST. Thrivent Financial for Lutherans purchased a new position in Twist Bioscience during the third quarter worth approximately $43,992,000. Point72 Asset Management L.P. increased its stake in shares of Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after acquiring an additional 613,057 shares during the last quarter. Fred Alger Management LLC raised its holdings in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after acquiring an additional 575,080 shares during the period. New York State Common Retirement Fund boosted its position in shares of Twist Bioscience by 1.8% during the 3rd quarter. New York State Common Retirement Fund now owns 482,606 shares of the company’s stock valued at $21,804,000 after acquiring an additional 8,529 shares during the last quarter. Finally, Driehaus Capital Management LLC grew its holdings in shares of Twist Bioscience by 63.0% in the second quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock valued at $19,152,000 after purchasing an additional 150,260 shares during the period.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CAO Robert F. Werner sold 1,448 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares of the company’s stock, valued at $2,034,652. This trade represents a 3.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Dennis Cho sold 1,507 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the sale, the insider now directly owns 91,163 shares in the company, valued at $4,375,824. This represents a 1.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock valued at $4,391,151 in the last three months. 3.92% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Robert W. Baird boosted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Scotiabank raised their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Barclays reduced their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Finally, Evercore ISI increased their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Twist Bioscience Trading Up 4.3 %

TWST stock opened at $48.32 on Thursday. The business’s fifty day moving average price is $43.75 and its 200 day moving average price is $46.20. Twist Bioscience Co. has a 12-month low of $23.07 and a 12-month high of $60.90. The company has a market capitalization of $2.87 billion, a PE ratio of -13.21 and a beta of 1.78.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.